#None #Pomerantz LLP #Vanda Pharmaceuticals #Hetlioz

Pomerantz Law Firm Investigates Claims Against Vanda Pharmaceuticals

The renowned Pomerantz LLP is delving into significant claims on behalf of investors in Vanda Pharmaceuticals Inc., a company listed on the NASDAQ under the ticker symbol VNDA. This investigation has arisen out of allegations concerning potential securities fraud and other unlawful business practices involving certain executives and/or directors at Vanda.

On January 8, 2026, Vanda Pharmaceuticals faced a considerable challenge when the U.S. Food and Drug Administration (FDA) issued a decision letter effectively halting the approval of their supplemental New Drug Application (sNDA) for HETLIOZ® (tasimelteon), which is intended for the treatment of jet lag disorder. The FDA acknowledged that while Vanda had garnered positive efficacy data from controlled clinical trials, these findings did not amount to substantial evidence for effectiveness in treating jet lag disorder. The FDA's conclusion was based on the assertion that the controlled phase advance protocols used in trials - involving bedtime changes of 5 to 8 hours - are not sufficiently comparable to actual jet travel, which entails additional complexities such as oxygen pressure variations, physical constraints, environmental noise, and shifts in lighting.

As a direct consequence of this unfavorable news, Vanda's share price saw a significant decline, dropping by $1.20 per share, which represented a notable 14.05% decrease, bringing the closing price down to $7.34 per share on the day following the FDA announcement.

Pomerantz LLP, recognized as a distinguished player in the fields of corporate, securities, and antitrust class litigation, has been in the fight for the rights of victims impacted by securities fraud and corporate misconduct for over 85 years. Founded by the late Abraham L. Pomerantz, often referred to as the dean of the class action bar, the firm has successfully recovered numerous multimillion-dollar damages for class members thwarted by corporate wrongdoing. The firm’s legacy includes a commitment to defending the rights of investors against any form of deceitful practices.

Investors who feel they have been wronged or misled regarding their investments in Vanda Pharmaceuticals are encouraged to reach out to Danielle Peyton at Pomerantz LLP for more information about joining the ongoing investigation or potential class action. With contacts available at [email protected] or by calling 646-581-9980, ext. 7980, the firm aims to ensure that investors receive the necessary support and guidance during this tumultuous period.

With the FDA's latest declaration casting doubt on Vanda's future regarding HETLIOZ, investors are urged to stay informed and consider their options carefully as they navigate the complexities of corporate securities law. This investigation is another reminder of the challenges faced by pharmaceutical companies in securing necessary approvals and the implications these setbacks can have on investor confidence and stock performance. For up-to-date information concerning this developing story, keep an eye on financial news outlets and company announcements.